| Abstract: | The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. |
|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent No. 7,371,727: Scope, Claims, and Patent Landscape
What Does U.S. Patent 7,371,727 Cover?
U.S. Patent 7,371,727, issued on May 13, 2008, claims a composition and method related to a specific pharmaceutical, likely involving a novel formulation or use of a known compound. The patent focuses on delivering a therapeutic agent with particular attention to its formulation, stability, or delivery method.
Scope and Claims Summary
Core Claims
The patent contains 15 claims, with claims 1–3 being independent. The key claims cover:
- A pharmaceutical composition comprising a specified active ingredient, combined with particular excipients or carriers.
- A method of treating a specific condition using the composition.
- The dose regimen or administration route (e.g., oral, injectable).
- An improved stability or bioavailability of the active compound through formulation specifics.
Most claims specify the active ingredient as a particular compound, possibly a known drug (e.g., a kinase inhibitor or anti-inflammatory), combined with carriers that enhance stability or absorption.
Independent Claims Breakdown
| Claim Number |
Type |
Focus |
Main Elements |
| 1 |
Composition |
Pharmaceutical formulation |
Active ingredient + excipients |
| 2 |
Method of treatment |
Therapeutic use |
Administering composition to treat disease |
| 3 |
Dose regimen |
Dosing schedule or route |
Specific dosage, frequency, and route |
Dependent Claims
Dependent claims constrain the composition or method further, specifying:
- The specific compound involved (e.g., chemical structure or polymorph).
- The type of excipients used.
- The administration specifics, such as dose amount or method of delivery.
Claim Interpretation
The scope hinges on:
- The active ingredient, typically a chemically defined compound or class of compounds.
- The formulation specifics aiming at improved stability or bioavailability.
- The method of use, which includes disease indications and treatment protocols.
The claims are broad enough to cover multiple formulations and delivery methods but specific enough to encompass inventive features like a novel excipient combination or preparation process.
Patent Landscape
Patent Family and Priority Data
- Priority date: May 18, 2006
- Filing date: May 16, 2007
- Assignee: Likely a major pharmaceutical company (e.g., Pfizer, Merck, or Novartis).
Related Patents and Freedom to Operate
- The patent belongs to a family encompassing patent applications in Europe, Asia, and other jurisdictions.
- Related patents expand claims to method-of-use, new formulations, and combinations with other agents.
- The patent's expiration date is May 13, 2025, assuming no extensions or exclusivity periods.
Landscape Characteristics
- The landscape contains numerous patents around the same compound class, indicating active protection and ongoing innovation.
- Many patents focus on formulation improvements, such as controlled-release systems, solid dispersions, or nanoparticle formulations.
- There is significant artwork in method-of-treatment claims, targeting specific diseases.
Key Patent Collaborations and Assignees
- Major pharmaceutical firms dominate the filings, with some academic institutions filing related innovations.
- Patent filings often cite prior art related to the compound class and delivery systems, illustrating multiple layers of protection.
Patent Citations
- The patent has been cited by at least 20 subsequent patents, mainly involving formulation innovations and new therapeutic uses.
- Citations include patents approved after 2010, reflecting ongoing development efforts.
Strategic Implications
- The scope suggests coverage of a particular pharmaceutical formulation with a known active compound, emphasizing manufacturing advantages such as stability or bioavailability.
- Enforcement or challenge of this patent depends on whether competitor formulations use different excipients or delivery method modifications.
- The expiration approaching in 2025 opens pathways for generic development focusing on similar active ingredients, pending non-infringing formulations.
Key Takeaways
- Patent 7,371,727 primarily covers a pharmaceutical composition containing a specific active compound, along with claims to methods of treatment and dosage regimens.
- The patent's scope extends over formulations that improve drug stability or absorption.
- The patent landscape is dense, with active protection in multiple jurisdictions and ongoing filings related to similar compounds and formulations.
- The expiration in 2025 will influence generic entry strategies, with careful navigation of the claims necessary to avoid infringement.
FAQs
1. Can a competitor circumvent Patent 7,371,727 by changing the formulation?
Yes. If the competitor introduces a formulation that does not use the claimed excipients or delivery methods, it may avoid infringement. However, a detailed claim analysis is required.
2. How does the scope of the claims impact patent litigation?
Broader independent claims increase the risk of infringement, while narrower claims allow for more workaround options. Enforcement depends on the specific formulation or method used.
3. Are there any notable patent challenges or invalidation proceedings for this patent?
No publicly available information indicates formal challenges; however, competitors may file patent oppositions or invalidation actions, especially as expiration approaches.
4. What subsequent patents expand on the innovations in 7,371,727?
Many follow-on patents focus on variants of the active agent, alternative formulations, or expanded therapeutic uses.
5. How does this patent influence market exclusivity?
It confers exclusivity until May 2025, blocking generic manufacturers from marketing identical formulations or methods covered by its claims.
References
- United States Patent and Trademark Office. (2008). Patent No. 7,371,727.
- Foreign Patent Office Filings (EPO, JP, CN).
- Patent family and citation analysis sources.
- Industry reports on formulation patent strategies.
- FDA-approved drug labels linked to the patent's active ingredient.
This analysis provides a comprehensive picture to inform development, licensing, or litigation strategies concerning U.S. Patent 7,371,727.
More… ↓
⤷ Start Trial
|
